Lymphoma

Clinically relevant variants were detected in 64% of samples, with negative results informing response or ruling out central nervous system lymphomas.

Findings from the phase 3 SWOG 1826/CA209-8UT trial support the regulatory decision for this lymphoma population.

An independent data monitoring committee advised that the risks associated with emergent secondary hematologic malignancies may outweigh the benefits.

Peter Martin, MD, focused on the collaborative meeting setting and where the MCL research field is headed.

Kami Maddocks, MD, discusses how the push to define high-risk MCL for clinical trials was a focus at the 2025 MCL workshop.

Frontline acalabrutinib tablets have been approved by the FDA for the treatment of CLL and SLL.

Michael Wang, MD, discusses the impact of the MCL Scientific Consortium on the lymphoma community.

A Prescription Drug User Fee Act date of December 18, 2026, has been set for tirabrutinib in this relapsed/refractory group.

The role of bispecific antibodies in mantle cell lymphoma treatment remains unclear, and they are not readily available in community sites, according to Tycel Phillips, MD.

Experts convene at the 2025 MCL Scientific Consortium to spark collaborations, advance novel therapies, and boost patient outcomes through foundation-driven research support.

Julie M. Vose, MD, MBA, details insights from the Mantle Cell Lymphoma Scientific Consortium and Workshop, focusing on global clinical trial collaboration and sequencing BTK/BCL-2 inhibitors.

TRX103 could foster a durable tolerizing environment, with regulatory cell levels matching those of healthy donors by day 42 post-transplant.

New MCL research spotlights BTK inhibitors, CAR-T advances, MRD-guided trials, and TP53-driven risk, reshaping frontline and relapse care.

Further research will investigate rates of adverse effects among patients treated with liso-cel in the real world vs a clinical trial setting.

Confirmed antilymphoma responses occurred in 75% of patients with lymphoma, including 2 with a complete response and 2 with a partial response.

CAR T-cell therapies displayed strong efficacy and manageable safety across lymphoma populations at the 2026 Tandem Meetings.

Phase 1 QUILT-3.002 data showed that combining an IL-15 superagonist with rituximab achieved a 78% CR rate in those with rituximab-refractory disease.

Approval of the larger vial size may offer more dosing flexibility for pediatric and adult patients with T-cell ALL or LBL.

Any-grade treatment-emergent immune-mediated AEs occurred in 22% of patients with early-stage lymphoma treated with the ADC-based regimen.

Findings from the phase 1b/2 TENACITY-01 trial, which is assessing CTD402 monotherapy in these hematologic malignancies, supported the agency’s decision.

Findings from the phase 1/2 BRUIN trial support the Notice of Compliance with conditions for pirtobrutinib in this relapsed/refractory disease population.

Data from a phase 1/2 trial support the FDA’s designation for WU-CART-007 in relapsed/refractory T-cell ALL and T-cell lymphoblastic lymphoma.

Epcoritamab did not demonstrate a significant improvement in OS, but improvements were observed in PFS, ORR, and DOR in this DLBCL group.

A disease control rate of 100% was attained among 4 patients with Waldenström lymphoma treated with the CAR-NK cell therapy.

The majority of patients with de novo DLBCL who received zanubrutinib plus rituximab and lenalidomide achieved complete responses in a phase 2 trial.